Shots:

• The company has submitted MAA for Omburtamab to EMA for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma
• The company continues to advance the Omburtamab program addressing the unmet medical need globally and work closely with FDA to resubmit the BLA in Q2 or Q3’21
• Y-mAbs get an exclusive license from MSK while MSK has an institutional financial interest related to the compound and Y-mAbs. Omburtamab is mAb targeting B7-H3 and is radiolabeled before intraventricular CNS administration

  Ref: GlobeNewswire | Image: Y-mabs